[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371295-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371295-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","gut-microbiome-features-associate-with-immune-checkpoint-inhibitor-response-in-individuals-with-non-melanoma-skin-cancers-an-exploratory-study","Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers - an exploratory study","","Immune checkpoint inhibitor (ICI) therapy benefits only a subset of individuals with skin cancer, motivating the search for predictive biomarkers. This exploratory study tests whether gut microbiota structure and function relate to ICI outcomes in non-melanoma skin cancers. Longitudinal 16S rRNA V1–V2 sequencing of 68 fecal samples and tumor-dependent differential analyses were combined with untargeted fecal metabolomics. Ten bacterial genera differed between responders and non-responders across tumor types, with CSCC showing additional genus/species and enriched pathways. Metabolomics linked predicted KEGG pathways to ICI efficacy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/gut-microbiome-features-associate-with-immune-checkpoint-inhibitor-response-in-individuals-with-non-melanoma-skin-cancers-an-exploratory-study/371295/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/gut-microbiome-features-associate-with-immune-checkpoint-inhibitor-response-in-individuals-with-non-melanoma-skin-cancers-an-exploratory-study/371295.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is this study focused on non-melanoma skin cancers instead of melanoma?","Question",{"text":63,"@type":64},"Prior microbiome–ICI associations were mainly studied in melanoma, where ICI use was first approved. Evidence for non-melanoma skin cancers remained limited.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were ICI responders and non-responders defined?",{"text":68,"@type":64},"Best overall response was determined by RECIST v.1.1: partial/complete responses were responders, while progressive disease defined non-responders.",{"name":70,"@type":61,"acceptedAnswer":71},"What experimental data types were used to connect gut microbiota with ICI outcomes?",{"text":72,"@type":64},"The study used longitudinal 16S rRNA V1–V2 gene amplicon sequencing for microbial composition and untargeted metabolomics with predicted functional pathway analyses to relate microbiota features to response.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371295,1790670015,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":102,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","| Open Peer Review | Computational Biology | Observation  \nGut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study  \nYujie Zhao,1 Jacqueline T. Ferri,2 James R. White,3 Megan D. Schollenberger,2 Kim Peloza,2 Cynthia L. Sears,2,4,5 Evan J. Lipson,2,5 Fyza Y. Shaikh2,5  \nAUTHOR AFFILIATIONS See affiliation list on p. 5.  \nABSTRACT Immune checkpoint inhibitor (ICI) therapy has yielded revolutionary outcomes among some individuals with skin cancer, but a large percentage of individuals do not benefit from these treatments. The gut microbiota is hypothesized to impact ICI therapy outcomes. However, data on ICI therapy, gut microbiota, and non-melanoma skin cancers are limited. To examine the association of gut microbiota structure and function with non-melanoma skin cancer ICI outcomes, we performed 16S rRNA V1-V2 gene amplicon sequencing of 68 fecal samples collected longitudinally from individuals with basal cell carcinoma (n = 5), Merkel cell carcinoma (n = 5), or cutaneous squamous cell carcinoma (CSCC, n = 11), followed by tumor-dependent differential analyses of bacterial composition and fecal sample analysis by untargeted metabolomics. Across all tumor types, we identified 10 differential bacterial genera between responders (R) or non-responders (NR) to ICI therapy. Among individuals with CSCC, we identified 10 genera and 20 species that differentiated between R and NR and yielded 8 pathways enriched in NR and 12 pathways enriched in R by predicted functional pathway analyses. Untargeted fecal metabolomics to examine putative gut microbiota metabolites associated with CSCC ICI R/NR identified nine KEGG pathways associated with ICI efficacy. In summary, this exploratory study suggests gut microbiota features that are associated with ICI efficacy in individuals with non-melanoma skin cancers and highlights the need for larger studies to validate the results.  \nIMPORTANCE Prior studies examining associations between ICI efficacy and the gut microbiome have focused primarily on individuals with melanoma, for whom ICI therapy was first approved. Meanwhile, data regarding microbiome features associated with ICI responses in individuals with non-melanoma skin cancers (NMSCs) have remained limited. This initial fecal microbiota examination of individuals with NMSCs suggests that larger-scale studies to extend and validate our findings may yield predictive or prognostic biomarkers for individuals with NMSC receiving ICI with potential to provide insight to complementary, effective therapeutic interventions through microbiota modification.  \nKEYWORDS microbiome, immune checkpoint inhibitors, cutaneous squamous cell carcinoma, Merkel cell carcinoma, basal cell carcinoma  \nA lthough immune checkpoint inhibitors (ICIs) have revolutionized care for individ  \nuals with advanced non-melanoma skin cancers (NMSCs), a substantial portion of individuals experience limited benefit from these drugs. Thus, there is a growing need to identify predictive and prognostic biomarkers to guide clinical decisions and optimize individual outcomes. Among many factors, the gut microbiota appears to play an important role in influencing ICI treatment efficacy. Preclinical studies  \nEditor Jan Claesen, Lerner Research Institute, Cleveland, Ohio, USA  \nAddress correspondence to Cynthia L. Sears, [csears@jhmi.edu](csears@jhmi.edu).  \nCynthia L. Sears, Evan J. Lipson, and Fyza Y. Shaikh are joint senior authors.  \nF.Y. S. reports research grants from Bristol Myers Squibb. J. R.W. reports equity ownership of Resphera Biosciences. C. L. S. reports research grants from Bristol Myers Squibb and Janssen and royalties from Up to Date, outside the submitted work. E.J. L. is a consultant/advisor for Bristol Myers Squibb, CareDx, Eisai, Genentech, HUYA Bioscience International, Immunocore, Instil Bio, Merck, Merck KGaA, Natera, Nektar, Novartis, OncoSec, Pfizer, Rain Therapeutics, Rege","cbCaibGyrmPknky1","https://ap.wps.com/l/cbCaibGyrmPknky1","pdf",741245,"English","# Abstract\n## Study design and sample collection\n## Microbiome composition and differential findings\n## Pathway and metabolomics results\n## Conclusions and need for validation","[{\"question\":\"Why is this study focused on non-melanoma skin cancers instead of melanoma?\",\"answer\":\"Prior microbiome–ICI associations were mainly studied in melanoma, where ICI use was first approved. Evidence for non-melanoma skin cancers remained limited.\"},{\"question\":\"How were ICI responders and non-responders defined?\",\"answer\":\"Best overall response was determined by RECIST v.1.1: partial/complete responses were responders, while progressive disease defined non-responders.\"},{\"question\":\"What experimental data types were used to connect gut microbiota with ICI outcomes?\",\"answer\":\"The study used longitudinal 16S rRNA V1–V2 gene amplicon sequencing for microbial composition and untargeted metabolomics with predicted functional pathway analyses to relate microbiota features to response.\"}]","Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers - an exploratory study | PDF",1790191728,15,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1df3df2ffdeab12b9a63d05514321e7.webp",983,1315,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aefde636c11a200c6c420951e0942cb0.webp",982,1314,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cde17e37a365cb7aefbfc98d2ade509.webp",981,1312,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c4e25162576347cc5d36b42ebf2082b.webp",980,1311]